Oxazolidinone antimicrobials: a patent review (2012-2015)

References

• Torrice M. Antibacterial boom and bust. C&EN. 2013;91:34–37.
   Web of Science ®Google Scholar
• Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J Antibiot. 2013;66:571–591.
   PubMed Web of Science ®Google Scholar
• Butler MS, Cooper MA. Antibiotics in the clinical pipeline in 2011. J Antibiot. 2011;64:413–425.
   PubMed Web of Science ®Google Scholar
• Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Res Update. 2011;14:118–124.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U. Accelerating resistance, inadequate antibacterial drug pipelines and international responses. Int J Antimicrob Agents. 2012;39:295–299.
   PubMed Web of Science ®Google Scholar
• Piddock LJV. The crisis of no new antibiotics – what is the way forward? Lancet Infect Dis. 2012;12:249–253.
   PubMed Web of Science ®Google Scholar
• Davies SC. Chief medical officer annual report [ cited 2016 Jan 11]. Available from: https://www.gov.uk/government/ publications/chief-medical-officer-annual-report-volume-2
   Google Scholar
• Frieden T. Director, U.S. Centers for Disease Control and Prevention [ cited 2016 Jan 11]. Available from: http://www.cdc.gov/AB4F87A3-79A9-4312-94C1-98280AA2A41F/FinalDownload/DownloadId-F25F5D61DAD7062F381AD2837FD8F59B/AB4F87A3-79A9-4312-94C1-98280AA2A41F/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
   Google Scholar
• O’Neill J. UK review on antimicrobial resistance. Securing new drugs for future generations – the pipeline of antibiotics. 2015 [cited 2016 Feb 24]. Available from: http://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf
   Google Scholar
• O’Neill J. UK review on antimicrobial resistance. Safe, secure and controlled: managing the supply chain of antimicrobials. 2015 [cited 2016 Feb 24]. Available from: http://amr-review.org/sites/default/files/SafeSecureandControlledShortPaper.pdf
   Google Scholar
• O’Neill J. UK review on antimicrobial resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014 [cited 2016 Feb 24]. Available from: http://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
   Google Scholar
• Moellering RC, Fishman N. Antimicrobial resistance prevention initiative: proceedings of an expert panel of resistance. Am J Infect Control. 2006;34(5 Suppl):A1–S79.
   PubMed Web of Science ®Google Scholar
• Fauci AS, Touchette NA, Folkers GK. Emerging infectious diseases: a 10-Year perspective from the National Institute of allergy and infectious diseases. Emerg Infect Dis. 2005;11:519–525.
   PubMed Web of Science ®Google Scholar
• Ager S, Gould K. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect Drug Res. 2012;5:87–102.
   PubMedGoogle Scholar
• Bassetti M, Righi E. Development of novel antibacterial drugs to combat multiple resistant organisms. Arch Surg. 2015;400:153–165.
   Google Scholar
• Holmes NE, Howden BP. What’s new in the treatment of serious MRSA infection? Curr Opin Infect Dis. 2014;27:471–478.
   PubMed Web of Science ®Google Scholar
• Xu H-B, Jiang R-H, Li L, et al. Linezolid in the treatment of MDR-TB: a retrospective clinical study. Int J Tuberc Lung Dis. 2012;16:358–363.
   PubMed Web of Science ®Google Scholar
• Xu H-B, Jiang R-H, Li L, et al. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis. 2012;16:1588–1593.
   PubMed Web of Science ®Google Scholar
• Leach KL, Brickner SJ, Noe MC, et al. Linezolid, the first oxazolidinone antibacterial agent. Ann N Y Acad Sci. 2011;1222:49–54.
   PubMed Web of Science ®Google Scholar
• Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: A review of postmarketing data. Clin Infect Dis. 2006;42:1578–1583.
   PubMed Web of Science ®Google Scholar
• Meck JV, Martin DS, D’Aunno DS, et al. Pressor response to intravenous tyramine is a marker of cardiac, but not vascular, adrenergic function. J Cardiovasc Pharmacol. 2003;41:126–131.
   PubMed Web of Science ®Google Scholar
• Shaw KJ, Barbachyn MR. The oxazolidinones: past, present and future. Ann N Y Acad Sci. 2011;1241:48–70.
   PubMed Web of Science ®Google Scholar
• Balaji G, Maharani B, Ravichandran V, et al. Linezolid induced black hairy tongue. Indian J Pharmacol. 2014;46:653–654.
   PubMed Web of Science ®Google Scholar
• Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother. 1997;41:2132–2136.
   PubMed Web of Science ®Google Scholar
• Ippolito JA, Kanyo ZF, Wang D, et al. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem. 2008;51:3353–3356.
   PubMed Web of Science ®Google Scholar
• Gu B, Kelesidis T, Tsiodras S, et al. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother. 2013;68:4–11.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Flamm RK, Hogan PA, et al. Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States. Antimicrob Agents Chemother. 2014;58:1243–1247.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Deshpande LM, Jones RN. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Updates. 2014;17:1–12.
   PubMed Web of Science ®Google Scholar
• Shore AC, Brennan OM, Ehricht R, et al. Identification and characterization of the multidrug resistance gene cfr in a Panton–Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate. Antimicrob Agents Chemother. 2010;54:4978–4984.
   PubMed Web of Science ®Google Scholar
• LaMarre J, Mendes RE, Szal T, et al. The genetic environment of the cfr gene and the presence of other mechanisms account for the very high linezolid resistance of Staphylococcus epidermidis isolate 426-3147L. Antimicrob Agents Chemother. 2013;57:1173–1179.
   PubMed Web of Science ®Google Scholar
• Sivextro approval history June 2014 [ cited 2016 Jan 11]. Available from: http://www.drugs.com/history/sivextro.html
   Google Scholar
• Kisgen JJ, Mansour H, Unger NR, et al. Tedizolid: A new oxazolidinone antimicrobial. Am J Health-Syst Pharm. 2014;71:621–633.
   PubMed Web of Science ®Google Scholar
• Rybak JM, Marx K, Martin CA. Early experience with tedizolid: clinical efficacy, pharmacodynamics and resistance. Pharmacotherapy. 2014;34:1198–1208.
   PubMed Web of Science ®Google Scholar
• Locke JB, Finn J, Hilgers M, et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother. 2010;54:5337–5343.
   PubMed Web of Science ®Google Scholar
• Locke JB, Zurenko GE, Shaw KJ, et al. Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis. 2014;58(Suppl 1):S35–S42.
   PubMed Web of Science ®Google Scholar
• Rybak JM, Barber KE, Rybak MJ. Current and prospective treatments for multidrug-resistant Gram positive infections. Expert Opin Pharmacother. 2013;14:1919–1932.
   PubMed Web of Science ®Google Scholar
• Moellering RC Jr. Tedizolid: a novel oxazolidinone for Gram-positive infections. Clin Infect Dis. 2014;58(Suppl 1):S1–S3.
   PubMed Web of Science ®Google Scholar
• Flanagan S, Bartizal K, Minassian SL, et al. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother. 2013;57:3060–3066.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Love R, Adam H, et al. Tedizolid: A novel oxazolidinone with potent activity against multidrug-resistant Gram-positive pathogens. Drugs. 2015;75:253–270.
   PubMed Web of Science ®Google Scholar
• Im WB, Choi SH, Park J-Y, et al. Discovery of torezolid as a novel 5-hydroxymethyl oxazolidinone antibacterial agent. Eur J Med Chem. 2011;46:1027–1039.
   PubMed Web of Science ®Google Scholar
• Michalska K, Karpiuk I, Krol M, et al. Recent development of potent analogues of oxazolidinone antibacterial agents. Bioorg Med Chem. 2013;21:577–591.
   PubMed Web of Science ®Google Scholar
• Phillips OA, Sharaf L, D’Silva R, et al. Evaluation of the monoamine oxidases inhibitory activity of a small series of 5-(azole)methyl oxazolidinones. Eur J Pharm Sci. 2015;71:56–61.
   PubMed Web of Science ®Google Scholar
• Phillips OA, D’Silva R, Bahta TO, et al. Synthesis and biological evaluation of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives. Eur J Med Chem. 2015;106:120–131.
   PubMed Web of Science ®Google Scholar
• Stokes SS, Morningstar M, Kocis H, et al. New antibacterial agents: patent applications published in 2010. Pharm Pat Analyst. 2012;1:601–620.
   PubMedGoogle Scholar
• Keating TA, Lister T, Verheijen JC. New antibacterial agents: patent applications published in 2011. Pharm Pat Analyst. 2014;3:87–112.
   PubMedGoogle Scholar
• Rib-X Pharmaceuticals, Incorporated. Biaryl heterocyclic compounds and methods of making and using the same. EP1656 370. 2012.
   Google Scholar
• Rib-X Pharmaceuticals, Incorporated. Biaryl heterocyclic compounds and methods of making and using the same. US2012/0010200. 2012.
   Google Scholar
• Rib-X Pharmaceuticals, Incorporated. Biaryl heterocyclic compounds and methods of making and using the same. US2014/0073624. 2014.
   Google Scholar
• Rib-X Pharmaceuticals, Incorporated. Biaryl heterocyclic compounds and methods of making and using the same. EP2492 264. 2012.
   Google Scholar
• Melinta Therapeutics Incorporated. Biaryl heterocyclic compounds and methods of making and using the same. US2015/0072970. 2015.
   Google Scholar
• Dong-A ST Co. Limited. Oxazolidinone derivatives. US8420676. 2013.
   Google Scholar
• Dong-A ST Co. Limited. Oxazolidinone derivatives. US9163043. 2015.
   Google Scholar
• Dong-A ST Co. Limited. Novel oxazolidinone derivatives. US2014/0350059. 2015.
   Google Scholar
• Xuanzhu Pharma Co. Limited. Biaryl heterocyclic substituted oxazolidinone antibacterial drug. EP2762479. 2014.
   Google Scholar
• Trius Therapeutics, Incorporated. Oxazolidinone containing dimer compounds, compositions and methods to make and use. US8580767. 2013.
   Google Scholar
• Actelion Pharmaceuticals Limited. Oxazolidinone antibiotic derivatives. US8114867. 2012.
   Google Scholar
• Actelion Pharmaceuticals Limited. Oxazolidinone antibiotics. EP2905283. 2015.
   Google Scholar
• Actelion Pharmaceuticals Limited. Tricyclic oxazolidinone antibiotic compounds. EP2344495. 2014.
   Google Scholar
• Xuanzhu Pharmac Inc. Limited. Oxazolidinone antibiotics containing fused ring. EP2762480. 2014.
   Google Scholar
• Katoh I, Aoki T, Suzuki H et al. Oxazolidinone derivative having fused ring. US2011/0098471. 2011.
   Google Scholar
• Entasis Therapeutics Limited. Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections. WO2015/181637. 2015.
   Google Scholar
• Legochem Biosciences, Inc. Method for the preparation of (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4-(1H)-yl)phenyl)-5-substitutedmethyl)oxazolidin-2-one deivatives. US2013/0005967. 2013.
   Google Scholar
• Jeong J-W, Jung S-J, Lee H-H, et al. In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrob Agents Chemother. 2010;54:5359–5362.
   PubMed Web of Science ®Google Scholar
• The PEW Charitable Trusts. Antibiotics currently in clinical development. 2015 Dec 17 [cited 2016 Jan 25]. Available from: http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development
   Google Scholar
• Lee Pharma Limited. Novel oxazolidinone antibacterial compound. WO2015/068173. 2015.
   Google Scholar
• Morphochem Aktiengesellschaft Fur Kombinatorische Chemie. Oxazolidinone-quinolone hybrid antibacterials for the parenteral treatment or prophylaxis of bacterial diseases. WO2014/191075. 2014.
   Google Scholar
• Locher HH, Seiler P, Chen X, et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58:892–900.
   PubMed Web of Science ®Google Scholar
• Kali A, Charles MVP, Srirangaraj S. Cadazolid: a new hope in the treatment of Clostridium difficile infections. Australas Med J. 2015;8:253–262.
   PubMed Web of Science ®Google Scholar
• University of South Florida. Derivative N-thiolated 2-oxazolidinone antibiotics. US8703963. 2014.
   Google Scholar
• Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Nanjing Changao Pharmaceutical Science and Technology Company Limited. Benzoxazine oxazolidinones compound, preparation method and application thereof. US 2015/0336984. 2015.
   Google Scholar
• Sichuan University and Sichua Gooddoctor Pharmaceutical Group Company Limited. Oxazolidinone compounds and their uses in preparation of antibiotics. US 2014/0142144. 2014.
   Google Scholar
• Council of Scientific and Industrial Research. Sila analogs of oxazolidinone derivatives and synthesis thereof. US 2014/0296133. 2014.
   Google Scholar
• Pandit N, Singla RK, Shrivastava B. Current updates on oxazolidinone and its significance. Internat J Med Chem. 2012; 2012(Article ID 159285):1–24.
   Google Scholar
• Venkanna G, Madhusudhan G, Mukkanti K, et al. A facile construction of 5-methylazido-3-aryl 2-oxazolidinone: a key precursor for the synthesis of Linezolid. Der Pharma Chemica. 2012;4(1):428–436.
   Google Scholar
• Tammana R, Vemula KK, Guruvindapalli R, et al. An expeditious construction of 3-aryl-5-(substituted methyl)-2-oxazolidinones: a short and efficient synthesis of Linezolid. ARKIVOC. 2012;vi:45–56.
   Google Scholar
• Brickner SJ, Hutchinson DK, Barbachyn MR, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem. 1996;39:673–679.
   PubMed Web of Science ®Google Scholar
• Lee Pharma Limited. Novel process for preparation of linezolid and its novel intermediates. EP2595968. 2015.
   Google Scholar
• Lee Pharma Limited. Novel process for preparation of linezolid and its novel intermediates. US2013/0324719. 2013.
   Google Scholar
• Lee Pharma Limited. Novel process for preparation of linezolid and its novel intermediates. WO2012/114355. 2012.
   Google Scholar
• Reddy PK, Mukkanti K, Rao DM. A novel synthesis of oxazolidinone derivatives (A Key Intermediate of Linezolid). Orient J Chem. 2013;29:1015–1019.
   Google Scholar
• Medscape Medical News (2016). Big Pharma pledges to develop new antibiotics, with help [cited 2016 Jan 27]. Available from: http://www.medscape.com/viewarticle/857627?nlid=98083_1842&src=wnl_edit_medp_wir&uac=35373HV&spon=17&impID=970260&faf=1
   Google Scholar